CONTERA PHARMA A/S: Financial statements 2015
CVR: 33062214
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 445,321 and a net result of DKK -1,083,182 compared with DKK -3,237,004 the year before. Equity in the 2015 report amounted to DKK 600,530. The solvency ratio was 70.5%.
- Gross Profit
- DKK 445,321
- Profit/Loss
- DKK -1,083,182
- Equity
- DKK 600,530
- Total Assets
- DKK 852,251
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 445 t. | -1.1 mio. | 601 t. | - |
| 2014 | - | -126 t. | -3.2 mio. | 1.7 mio. | - |
| 2013 | - | -3.4 mio. | -4.7 mio. | 1.7 mio. | - |
| 2012 | - | -3.7 mio. | -4.2 mio. | 6.4 mio. | - |
Official annual report
How creditworthy is CONTERA PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
CONTERA PHARMA A/S has published its annual report for 2014. Gross profit came to DKK -125,656, and the net result was DKK -3,237,004.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.